CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Pfizer
Main (gene editing) focus: In vivo base editing for genetic diseases
Company stage: Commercial
Diseases (gene editing): Rare genetic diseases of the liver, muscle and central nervous system
Genome editing tool: Base editing
Funding stage: Public (NASDAQ:PFE)
Location: New York City, New York, USA
Website: https://www.pfizer.com/
Pipeline: https://www.pfizer.com/science/drug-product-pipeline
Gene editing partnerships: Beam Therapeutics
Pfizer is an established big pharma company with worldwide operations and drug discovery activities within many different areas. The company's engagement in the gene-editing space comes through its collaboration with Beam Therapeutics. The two companies will develop novel in vivo gene-editing programmes against targets within disease areas involving the liver, muscle and central nervous system (CNS).
